Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 12, 2015, Pages 4588-4594

  Mikkola, Tomi S ^a,b   Tuomikoski, Pauliina ^a   Lyytinen, Heli ^c   Korhonen, Pasi ^c   Hoti, Fabian ^c   Vattulainen, Pia ^c   Gissler, Mika ^d,e   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c EPID Research Oy   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FINN (CITIZEN); HEART DEATH; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; REIMBURSEMENT; RISK REDUCTION; AGE; AGED; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ESTROGEN THERAPY; FINLAND; FOLLOW UP; MIDDLE AGED; MORTALITY; REGISTER; RISK; WITHDRAWAL SYNDROME;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; REGISTRIES; RISK; STROKE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84951036752     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1864     Document Type: Article

References (39)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
2. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.Aprospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women?s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women?s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
5. Bretler DM, Hansen PR, Sorensen R, et al. Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. BMJ. 2012;344:e1802.
6. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(suppl 1):S7-S66.
7. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficultywhendiscontinuing postmenopausal hormone therapy. Obstet Gynecol. 2003;102:1233-1239.
8. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
9. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.
10. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dosedependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994;90:1964-1968.
11. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol. 2009;71: 785-793.
12. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688-708.
13. Maranon R, Reckelhoff JF. Sex and gender differences in control of blood pressure. Clin Sci (Lond). 2013;125:311-318.
14. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133-136.
15. Ciccone MM, Scicchitano P, Gesualdo M, et al. Systemic vascular hemodynamic changes due to 17-estradiol intranasal administration. J Cardiovasc Pharmacol Ther. 2013;18:354-358.
16. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol. 2007;94:265-319.
17. Buber J, Mathew J, Moss AJ, et al. Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation. 2011;123:2784-2791.
18. Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the QT interval: a review. J Womens Health (Larchmt). 2012;21:933-941.
19. Lahti RA, Sarna S, Penttilä A. Exploitation of autopsy in determining natural cause of death: trends in Finland with special reference to the diagnostics of ischemic heart diseases and cerebrovascular diseases in middle-aged males, 1974-1993. Forensic Sci Int. 1998; 91:109-121.
20. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998.
21. Tuomikoski P, Lyytinen H, Korhonen P, et al. Coronary heart disease mortality and hormone therapy before and after the Women?s Health Initiative. Obstet Gynecol. 2014;124:947-953.
22. Mikkola TS, Clarkson TB. Estrogen replacement therapy, athero sclerosis, and vascular function. Cardiovasc Res. 2002;53:605-619.
23. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception. 2007;75:S155-S160.
24. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114:1197-1204.
25. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women?s Health Initiative randomized trials. JAMA. 2013;310:1353-1368.
26. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. AnnNYAcad Sci. 2006;1089:424-430.
27. Farag NH, Bardwell WA, Nelesen RA, Dimsdale JE, Mills PJ. Autonomic responses to psychological stress: the influence of menopausal status. Ann Behav Med. 2003;26:134-138.
28. Hoikkala H, Haapalahti P, Viitasalo M, et al. Association between vasomotor hot flashes and heart rate variability in recently postmenopausal women. Menopause. 2010;17:315-320.
29. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74:224-242.
30. Nelson HD. Menopause. Lancet. 2008;371:760-770.
31. Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc. 2013;61:1005-1010.
32. Lehto HR, Lehto S, Havulinna AS, et al. Sex differences in short- and long-term case-fatality of myocardial infarction. Eur J Epidemiol. 2011;26:851-861.
33. Bretler DM, Hansen PR, Abildstrøm SZ, et al. Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol. 2011;71:105-115.
34. Meretoja A, Roine RO, Kaste M, et al. Stroke monitoring on a national level: PERFECT Stroke, a comprehensive, registry-linkage stroke database in Finland. Stroke. 2010;41:2239-2246.
35. Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI. Sex differences in mortality after myocardial infarction. Is there evidence for an increased risk for women? Circulation. 1995;91:1861-1871.
36. Andrikopoulos GK, Tzeis SE, Pipilis AG, et al. Investigators of the Hellenic Study of AMI. Younger age potentiates post myocardial infarction survival disadvantage of women. Int J Cardiol. 2006; 108:320-325.
37. Kaul P, Armstrong PW, Sookram S, Leung BK, Brass N, Welsh RC. Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. Am Heart J. 2011;161:91-97.
38. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65-73.
39. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas. 1999;32:141-145.